Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL888000 | 0.92 | ADORA3 (0.43) | PRMT6ADORA3ADORA2AADORA1P2RY12 | |
| SCHEMBL7873202 | 0.91 | ADORA2A (0.42) | PRMT6ADORA3ADORA2AADORA1P2RY12 | |
| SCHEMBL5354472 | 0.90 | ADORA3 (0.41) | PRMT6ADORA3ADORA2AADORA1P2RY12 | |
| SCHEMBL439195 | 0.85 | PRMT5 (0.45) | ADORA3ADORA2AP2RY12 | |
| SCHEMBL2112012 | 0.84 | ADORA3 (0.43) | PRMT6ADORA3P2RY12 | |
| SCHEMBL7523809 | 0.83 | PRMT5 (0.45) | ADORA3ADORA2AP2RY12 | |
| SCHEMBL888001 | 0.83 | ADORA3 (0.45) | ADORA3ADORA2AADORA1P2RY12 | |
| SCHEMBL2112346 | 0.81 | ADORA3 (0.43) | ADORA3ADORA2AADORA1P2RY12PAX8 | |
| SCHEMBL887979 | 0.80 | PRMT6 (0.36) | PRMT6ADORA3ADORA2AADORA1P2RY12 | |
| SCHEMBL9773291 | 0.78 | ADORA3 (0.40) | ADORA3ADORA2AADORA1PAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6169170-B1 | DUPLEX OLIGONUCLEOTIDE OF TWO COMPLEMENTARY STRANDS WHERE AT LEAST ONE STRAND HAS AT LEAST FIFTY PERCENT PHOSPHORAMIDATE LINKAGES AND AT LEAST TWO LINKAGES ARE CONSECUTIVE; ANTISENSE AGENTS WITH INCREASED PHOSPHODIESTERASE RESISTANCE | LYNX THERAPEUTICS, INC. | 2001-01-02 | — | — | US | disclosed |
| EP-0754242-A4 | OLIGONUCLEOTIDE N3'-m(7)P5' PHOSPHORAMIDATES: SYNTHESIS AND COMPOUNDS; HYBRIDIZATION AND NUCLEASE RESISTANCE PROPERTIES | LYNX THERAPEUTICS INC (US) | 1997-06-11 | — | — | EP | disclosed |
| EP-0754242-A1 | OLIGONUCLEOTIDE N3'$m(7)P5' PHOSPHORAMIDATES: SYNTHESIS AND COMPOUNDS; HYBRIDIZATION AND NUCLEASE RESISTANCE PROPERTIES | LYNX THERAPEUTICS, INC. (US) | 1997-01-22 | — | — | EP | disclosed |
| WO-1995025814-A1 | OLIGONUCLEOTIDE N3'→P5' PHOSPHORAMIDATES: SYNTHESIS AND COMPOUNDS; HYBRIDIZATION AND NUCLEASE RESISTANCE PROPERTIES | LYNX THERAPEUTICS, INC. (US) | 1995-09-28 | — | — | WO | disclosed |